| Michael Patrick Miller |
Michael Patrick Miller is on the board of The Leukemia & Lymphoma Society, Inc., Puma Biotechnology, Inc. and Zane Beadles Parade Foundation.
Mr. Miller previously was Chief Commercial Officer & Senior Vice President at VIVUS, Inc., Executive Vice President-Commercial at Jazz Pharmaceuticals Plc, Vice President at ALZA Corp., Vice President-Commercial Operations at Cellegy Pharmaceuticals, Inc., Vice President-Sales & Marketing for Genentech, Inc. and Senior Vice President-Sales & Marketing for Connetics Corp.
He received an undergraduate degree from the University of San Francisco and an MBA from San Francisco State University. |
| Jay M. Moyes |
Jay M. Moyes is on the board of Puma Biotechnology, Inc., BioCardia, Inc. and Achieve Life Sciences, Inc. and Member of Utah Association of Certified Public Accountants and Managing Member at Drayton Investments LLC.
In his past career Mr. Moyes was Chief Financial Officer of Myriad Genetics, Inc., Chief Financial Officer for CareDx, Inc., Chief Financial Officer & Director at SINTX Technologies, Inc., Chief Financial Officer & Vice President-Finance of Genmarks, Inc. and Senior Manager at KPMG LLP.
Mr. Moyes received an MBA from the University of Utah and an undergraduate degree from Weber State University. |
| Alan H. Auerbach |
Alan H. Auerbach founded Cougar Biotechnology, Inc. and Puma Biotechnology, Inc. Currently, Mr. Auerbach is Chairman, President, CEO & Secretary at Puma Biotechnology, Inc.
In the past he held the position of Vice President of Seidler Cos., Inc., Chairman, President & Chief Executive Officer for Innovative Acquisitions Corp., President, Chief Executive Officer & Director at Cougar Biotechnology, Inc., Vice President & Senior Research Analyst at Diagnostic Products Corp. and Vice President & Senior Research Analyst at Wells Fargo Securities (Old).
He received an undergraduate degree from Boston University and a graduate degree from the University of Southern California. |
| Mariann Ohanesian |
Currently, Mariann Ohanesian occupies the position of Senior Director-Investor Relations at Puma Biotechnology, Inc. and Director-Investor Relations for Janssen Oncology, Inc. |
| Adrian M. Senderowicz |
Adrian M. Senderowicz is on the board of Puma Biotechnology, Inc. He previously held the position of Chief Medical Officer & Senior Vice President of Constellation Pharmaceuticals, Inc., Chief Medical Officer & Senior Vice President for Daré Bioscience, Inc. and Chief Medical Officer & Senior Vice President of Cerulean Pharma, Inc. (a subsidiary of Daré Bioscience, Inc.), Senior Medical Director-Oncology Division at AstraZeneca Plc, Vice President-Global Regulatory Oncology at Sanofi, Chief Medical Officer & VP-Medical Development at Tokai Pharmaceuticals, Inc., Chief Medical Officer & SVP-Regulatory Affairs at Ignyta, Inc., Head-Prostate Cancer Clinic at National Institutes of Health and Clinical Team Leader-Oncology Division at US Food & Drug Administration.
Dr. Senderowicz received a doctorate from Universidad de Buenos Aires. |
| Troy E. Wilson |
Troy E. Wilson is an entrepreneur and businessperson who founded 5 companies, notably: Kura Oncology, Inc., Avidity Biosciences, Inc. and Ambrx, Inc. and who has been at the head of 8 different companies. Currently, he is Non-Executive Chairman at Avidity Biosciences, Inc. (which he founded in 2012), Chairman, President & Chief Executive Officer of Kura Oncology, Inc. (which he founded in 2014), Executive Chairman for Wellspring Biosciences LLC and Managing Member at Araxes Pharma LLC. Dr. Wilson is also on the board of Puma Biotechnology, Inc.
In his past career Troy E. Wilson held the position of President of Wildcat Discovery Technologies, Inc. (he founded the company), Chief Business Officer of Ambrx, Inc. (he founded the company in 2003), Founding Partner of Presidio Partners, Chairman, President & Chief Executive Officer at Zeta Acquisition Corp. III, President, Chief Executive Officer & Director at Intellikine LLC (he founded the company in 2007), Chief Executive Officer at Takeda Pharmaceuticals U.S.A., Inc. and Vice President-Business Development of Novartis Institute for Functional Genomics, Inc.
He received an undergraduate degree and a doctorate from the University of California, Berkeley and a graduate degree from New York University. |
| Hugh O'Dowd |
Hugh O'Dowd holds the position of Independent Non-Executive Chairman of ONK Therapeutics Ltd. He is also on the board of Puma Biotechnology, Inc.
In the past he held the position of President, Chief Executive Officer & Director at BioNTech US, Inc., President & General Manager at Novartis UK Ltd., President & General Manager at Novartis Ireland Ltd., Chief Commercial Officer & Head-Global Strategy at Novartis Oncology, Inc. and General Manager for Novartis International Pharmaceutical Ltd.
He received an undergraduate degree from Loyola University of Chicago and an MBA from Kellstadt Graduate School of Business. |
| Brian M. Stuglik |
Mr. Brian M. Stuglik is an Independent Director at Puma Biotechnology, Inc., an Independent Director at Oncopeptides AB, a Chief Executive Officer & Director at Verastem, Inc., a Member at American Association for Cancer Research, a Member at American Society of Clinical Oncology and a Member at International Association for the Study of Lung Cancer. He is on the Board of Directors at Puma Biotechnology, Inc., Oncopeptides AB and Verastem, Inc. Mr. Stuglik was previously employed as a Founder by Proventus Health Solutions LLC and a Vice President by Eli Lilly & Co. He received his undergraduate degree from Purdue University. |
| Douglas Hunt |
Currently, Douglas Hunt is SVP-Regulatory Affairs & Medical Writing at Puma Biotechnology, Inc.
Mr. Hunt previously held the position of Executive Director-Therapeutic Area at Amgen, Inc., Vice President-Global Regulatory Affairs at Baxter Healthcare Corp. and VP-Regulatory Affairs & Quality Assurance at ArmaGen, Inc.
Mr. Hunt received an undergraduate degree from the University of Portsmouth. |
| Maximo F. Nougues |
Currently, Maximo F. Nougues is Chief Financial Officer for Puma Biotechnology, Inc.
He previously was Chief Financial Officer-North America Region at Getinge AB and Chief Financial Officer & Regional VP-Finance at MAQUET Cardiovascular LLC.
Mr. Nougues received a graduate degree from Universidad Del Norte Santo Tomas De Aquino and an MBA from Mclaren School of Business. |
| Ann Calby Miller |
Dr. Ann C. Miller, MD, is an Independent Director at Puma Biotechnology, Inc. and an Independent Director at Inovio Pharmaceuticals, Inc. She is on the Board of Directors at Allena Pharmaceuticals, Inc., Puma Biotechnology, Inc. and Inovio Pharmaceuticals, Inc. Dr. Miller was previously employed as a Vice President-Marketing & Global Marketing by Sanofi SA, a Senior Vice President-Pharmaceutical Services by Eisai Co., Ltd., and an Executive Director-Global Marketing by Amgen, Inc. She received her undergraduate degree from Duke University and a doctorate degree from Duke University School of Medicine. |
| Jeffrey Ludwig |
Jeffrey Ludwig is Chief Commercial Officer for Puma Biotechnology, Inc.
In the past Mr. Ludwig held the position of Vice President-Oncology Sales at Astellas Pharma, Inc. and Vice President-Oncology Sales at Amgen, Inc.
He received an undergraduate degree from Arizona State University. |
